Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
37
TCBP Quote, Financials, Valuation and Earnings
Last price:
$0.66
Seasonality move
:
-22.96%
Day range:
$0.61 - $0.67
52-week range:
$0.44 - $41.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.16x
Volume:
758.8K
Avg. volume:
2.4M
1-year change:
-96.77%
Market cap:
$5.5M
Revenue:
--
EPS (TTM):
-$70.64
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$20.5M | -$0.18 | 4199.24% | -9.44% | $3.50 |
|
AUTL
Autolus Therapeutics PLC
|
$155K | -$0.22 | -61.82% | -46.14% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$3.95 | -- | -98.11% | -- |
|
VRNA
Verona Pharma PLC
|
$2M | -$0.41 | -- | -2.08% | $47.29 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TCBP
TC BioPharm (Holdings) PLC
|
$0.67 | -- | $5.5M | -- | $0.00 | 0% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.60 | $3.50 | $154.8M | -- | $0.00 | 0% | 0.85x |
|
AUTL
Autolus Therapeutics PLC
|
$2.29 | -- | $609.4M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$3.90 | -- | $2.3M | -- | $0.00 | 0% | 3.52x |
|
NCNA
NuCana PLC
|
$1.20 | -- | $4.7M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$42.06 | $47.29 | $3.4B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -0.755 | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
38.4% | 5.180 | 20.51% | 3.54x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 4.339 | -- | 17.97x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -0.555 | -- | -- |
|
NCNA
NuCana PLC
|
-- | 1.608 | -- | -- |
|
VRNA
Verona Pharma PLC
|
47.91% | -0.070 | 5.1% | 12.47x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$14.7M | -55.22% | -67.8% | -38.33% | -$54.9M |
|
AUTL
Autolus Therapeutics PLC
|
-- | -$67.7M | -80.74% | -80.74% | -331.28% | -$86.3M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$6.6M | -- | -- | -- | -$6.4M |
|
VRNA
Verona Pharma PLC
|
$5.1M | -$39.1M | -55.17% | -74.15% | -583.75% | -$62.7M |
TC BioPharm (Holdings) PLC vs. Competitors
-
Which has Higher Returns TCBP or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to TC BioPharm (Holdings) PLC's net margin of -43.07%. TC BioPharm (Holdings) PLC's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.
Company Gross Margin Earnings Per Share Invested Capital TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M -
What do Analysts Say About TCBP or ADAP?
TC BioPharm (Holdings) PLC has a consensus price target of --, signalling upside risk potential of 349.17%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $3.50 which suggests that it could grow by 274.78%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe TC BioPharm (Holdings) PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings TCBPTC BioPharm (Holdings) PLC0 0 0 ADAPAdaptimmune Therapeutics PLC4 2 0 -
Is TCBP or ADAP More Risky?
TC BioPharm (Holdings) PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.179, suggesting its more volatile than the S&P 500 by 117.863%.
-
Which is a Better Dividend Stock TCBP or ADAP?
TC BioPharm (Holdings) PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TC BioPharm (Holdings) PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCBP or ADAP?
TC BioPharm (Holdings) PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. TC BioPharm (Holdings) PLC's net income of -$2.5M is higher than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, TC BioPharm (Holdings) PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TC BioPharm (Holdings) PLC is -- versus 0.85x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M ADAPAdaptimmune Therapeutics PLC0.85x -- $40.9M -$17.6M
-
Which has Higher Returns TCBP or AUTL?
Autolus Therapeutics PLC has a net margin of -- compared to TC BioPharm (Holdings) PLC's net margin of -522.15%. TC BioPharm (Holdings) PLC's return on equity of -- beat Autolus Therapeutics PLC's return on equity of -80.74%.
Company Gross Margin Earnings Per Share Invested Capital TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- AUTLAutolus Therapeutics PLC-- -$0.31 $582M -
What do Analysts Say About TCBP or AUTL?
TC BioPharm (Holdings) PLC has a consensus price target of --, signalling upside risk potential of 349.17%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 356.33%. Given that Autolus Therapeutics PLC has higher upside potential than TC BioPharm (Holdings) PLC, analysts believe Autolus Therapeutics PLC is more attractive than TC BioPharm (Holdings) PLC.
Company Buy Ratings Hold Ratings Sell Ratings TCBPTC BioPharm (Holdings) PLC0 0 0 AUTLAutolus Therapeutics PLC7 2 0 -
Is TCBP or AUTL More Risky?
TC BioPharm (Holdings) PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.984, suggesting its more volatile than the S&P 500 by 98.37%.
-
Which is a Better Dividend Stock TCBP or AUTL?
TC BioPharm (Holdings) PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TC BioPharm (Holdings) PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCBP or AUTL?
TC BioPharm (Holdings) PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $10.1M. TC BioPharm (Holdings) PLC's net income of -$2.5M is higher than Autolus Therapeutics PLC's net income of -$82.1M. Notably, TC BioPharm (Holdings) PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TC BioPharm (Holdings) PLC is -- versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M
-
Which has Higher Returns TCBP or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to TC BioPharm (Holdings) PLC's net margin of --. TC BioPharm (Holdings) PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- BDRXBiodexa Pharmaceuticals PLC-- -- -- -
What do Analysts Say About TCBP or BDRX?
TC BioPharm (Holdings) PLC has a consensus price target of --, signalling upside risk potential of 349.17%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of -- which suggests that it could grow by 105.52%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe TC BioPharm (Holdings) PLC is more attractive than Biodexa Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings TCBPTC BioPharm (Holdings) PLC0 0 0 BDRXBiodexa Pharmaceuticals PLC0 0 0 -
Is TCBP or BDRX More Risky?
TC BioPharm (Holdings) PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.447, suggesting its more volatile than the S&P 500 by 44.69%.
-
Which is a Better Dividend Stock TCBP or BDRX?
TC BioPharm (Holdings) PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TC BioPharm (Holdings) PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCBP or BDRX?
TC BioPharm (Holdings) PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. TC BioPharm (Holdings) PLC's net income of -$2.5M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, TC BioPharm (Holdings) PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TC BioPharm (Holdings) PLC is -- versus 3.52x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M BDRXBiodexa Pharmaceuticals PLC3.52x -- -- --
-
Which has Higher Returns TCBP or NCNA?
NuCana PLC has a net margin of -- compared to TC BioPharm (Holdings) PLC's net margin of --. TC BioPharm (Holdings) PLC's return on equity of -- beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- NCNANuCana PLC-- -$2.28 -- -
What do Analysts Say About TCBP or NCNA?
TC BioPharm (Holdings) PLC has a consensus price target of --, signalling upside risk potential of 349.17%. On the other hand NuCana PLC has an analysts' consensus of -- which suggests that it could grow by 4038.89%. Given that NuCana PLC has higher upside potential than TC BioPharm (Holdings) PLC, analysts believe NuCana PLC is more attractive than TC BioPharm (Holdings) PLC.
Company Buy Ratings Hold Ratings Sell Ratings TCBPTC BioPharm (Holdings) PLC0 0 0 NCNANuCana PLC3 1 0 -
Is TCBP or NCNA More Risky?
TC BioPharm (Holdings) PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NuCana PLC has a beta of 0.944, suggesting its less volatile than the S&P 500 by 5.593%.
-
Which is a Better Dividend Stock TCBP or NCNA?
TC BioPharm (Holdings) PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TC BioPharm (Holdings) PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCBP or NCNA?
TC BioPharm (Holdings) PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. TC BioPharm (Holdings) PLC's net income of -$2.5M is higher than NuCana PLC's net income of -$5.9M. Notably, TC BioPharm (Holdings) PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TC BioPharm (Holdings) PLC is -- versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M NCNANuCana PLC-- -- -- -$5.9M
-
Which has Higher Returns TCBP or VRNA?
Verona Pharma PLC has a net margin of -- compared to TC BioPharm (Holdings) PLC's net margin of -763.91%. TC BioPharm (Holdings) PLC's return on equity of -- beat Verona Pharma PLC's return on equity of -74.15%.
Company Gross Margin Earnings Per Share Invested Capital TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- VRNAVerona Pharma PLC90.35% -$0.56 $250.5M -
What do Analysts Say About TCBP or VRNA?
TC BioPharm (Holdings) PLC has a consensus price target of --, signalling upside risk potential of 349.17%. On the other hand Verona Pharma PLC has an analysts' consensus of $47.29 which suggests that it could grow by 12.42%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Verona Pharma PLC, analysts believe TC BioPharm (Holdings) PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings TCBPTC BioPharm (Holdings) PLC0 0 0 VRNAVerona Pharma PLC5 0 0 -
Is TCBP or VRNA More Risky?
TC BioPharm (Holdings) PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.579%.
-
Which is a Better Dividend Stock TCBP or VRNA?
TC BioPharm (Holdings) PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TC BioPharm (Holdings) PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCBP or VRNA?
TC BioPharm (Holdings) PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $5.6M. TC BioPharm (Holdings) PLC's net income of -$2.5M is higher than Verona Pharma PLC's net income of -$43M. Notably, TC BioPharm (Holdings) PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TC BioPharm (Holdings) PLC is -- versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M VRNAVerona Pharma PLC-- -- $5.6M -$43M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
